**SECTION B. HUMAN CSF PRODUCTION/ICP STUDIES WITH CA-INHIBITORS (ANY
INDICATION)**

STUDY_ID,PARENT_TRIAL_ID,FIRST_AUTHOR,YEAR,JOURNAL,FULL_CITATION_TEXT,DOI,SPECIES,COUNTRY_OR_REGION,POPULATION_CATEGORY,AGE_GROUP,N_SUBJECTS_TOTAL,DISEASE_LABEL_AS_REPORTED,INCLUDES_IIH_PTCS_PATIENTS,STUDY_DESIGN_MAIN,STUDY_DESIGN_DETAIL,PRIMARY_MEASUREMENT_METHOD,PRIMARY_MEASUREMENT_SITE,PRIMARY_CAI_NAME,PRIMARY_COMPARATOR_DESCRIPTION,PRIMARY_ENDPOINT_NAME,PRIMARY_ENDPOINT_TYPE,PRIMARY_ENDPOINT_MAIN_TIMEFRAME_AS_REPORTED,KEY_INCLUSION_CRITERIA_TEXT,KEY_EXCLUSION_CRITERIA_TEXT,FUNDING_SOURCE_TEXT,NOTES_INTERNAL_VALIDITY,PDF_SOURCE_IDENTIFIER

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,Ivkovic,2015,Fluids
Barriers CNS,\"Ivkovic et al. Fluids and Barriers of the CNS (2015)
12:9\",10.1186/s12987-015-0004-z,Human,USA /
Germany,iNPH,Adults,25,\"idiopathic normal pressure hydrocephalus
(iNPH)\",No,Prospective cohort,Serial MRIs and clinical assessments in
iNPH patients receiving ACZ or ELD vs controls.,MRI
(T1-DTI-ASL),Parenchymal,Acetazolamide,\"ACZ vs ELD vs
NoIntervention\",Change in T1-hypointensities volume and mean
diffusivity,Continuous,3 months (ACZ); 72 hours (ELD),Subjects met the
International Consensus Criteria for Probable iNPH and were not urgently
in need of shunt surgery.,General MRI contraindications (for ELD
cohort),NIH (R01NS052122); Leon Levy Foundation; ADNI,Small cohorts (N=8
ACZ N=12 ELD N=5 control); ACZ and ELD cohorts from different
centers.,12987_2015_Article_4.pdf

Birzis_1958_Neurology,Birzis_1958_Neurology,Birzis,1958,Neurology,\"Birzis
L, Carter CH, Maren TH. Effect of acetazolamide on CSF pressure and
electrolytes in hydrocephalus. Neurology.
1958;8(7):522-528\",NR,Human,USA,Infant
hydrocephalus,Infants/Children,10,hydrocephalus (communicating and
non-communicating),No,Acute physiology experiment,Serial CSF pressure
and electrolyte measurements before and after IV/IM
acetazolamide.,Ventricular/lumbar
puncture,Ventricular/Lumbar,Acetazolamide,Baseline vs post-ACZ,Change in
CSF pressure,Continuous,Hours after dose,Children with
hydrocephalus,NR,NR,Small N; mixed hydrocephalus types,birzis1958.pdf

Schoeman_1994_JChildNeurol,Schoeman_1994_JChildNeurol,Schoeman,1994,J
Child Neurol,\"Schoeman JF. Childhood tuberculous meningitis: is
acetazolamide and furosemide of value? J Child Neurol.
1994;9(2):148-151\",NR,Human,South Africa,TB meningitis
(children),Children,36,\"Tuberculous meningitis (Stages II and
III)\",No,Prospective cohort (non-randomized),Comparison of standard
therapy (N=18) vs standard + ACZ/furosemide (N=18) on ICP and clinical
outcome.,Epidural pressure monitoring,Epidural,Acetazolamide,\"Standard
therapy vs Standard + ACZ + Furosemide\",Change in ICP and clinical
outcome,Continuous / Ordinal,Daily ICP for 7 days (acute phase); 1 month
(diuretics total),Children (6 mos-13 yrs) with Stage II or III
tuberculous meningitis,NR,South African Medical Research
Council,Non-randomized; comparator is ACZ \*plus\*
furosemide,schoeman1994.pdf

Schain_1969_AmJDisChild,Schain_1969_AmJDisChild,Schain,1969,Am J Dis
Child,\"Schain RJ. Carbonic anhydrase inhibitors in chronic infantile
hydrocephalus. Am J Dis Child. 1969;117(6):621-625\",NR,Human,USA,Infant
hydrocephalus,Infants,16,Chronic infantile hydrocephalus,No,Case
series,Response to acetazolamide or other CAIs in infants with
hydrocephalus assessed by head circumference.,Head circumference;
Clinical assessment,NA,Acetazolamide,Baseline vs post-CAI,Arrest/slowing
of head circumference growth,Ordinal,Chronic (weeks to months),Infants
(\<1 yr) with chronic hydrocephalus,Rapidly advancing
hydrocephalus,NR,Uncontrolled case series; outcome is head circumference
(proxy for ICP),schain1969.pdf

Huttenlocher_1965_JPediatr,Huttenlocher_1965_JPediatr,Huttenlocher,1965,J
Pediatr,\"Huttenlocher PR. Treatment of hydrocephalus with
acetazolamide: results in 15 cases. J Pediatr.
1965;66(6):1023-1030\",NR,Human,USA,Infant
hydrocephalus,Infants,15,\"Hydrocephalus (slowly progressive)\",No,Case
series,Response to acetazolamide in infants with slowly progressive
hydrocephalus assessed by head circumference and ventricular size.,Head
circumference; Pneumoencephalography,NA,Acetazolamide,Baseline vs
post-ACZ,Arrest of hydrocephalus (clinical/imaging),Ordinal,Chronic
(months),Infants (\<1 yr) with slowly progressive hydrocephalus,Rapidly
progressive hydrocephalus,NR,Uncontrolled case series; outcome is
clinical/head circumference,PIIS0022347665800877.pdf

Silverberg_1998_Lancet,Silverberg_1998_Lancet,Silverberg,1998,Lancet,\"Silverberg
GD, Huhn S. Acetazolamide and furosemide in the treatment of normal
pressure hydrocephalus. Lancet.
1998;351(9097):216\",NR,Human,USA,iNPH,Adults,12,Normal pressure
hydrocephalus,No,Case series,Small case series reporting clinical
response to ACZ + furosemide in NPH.,Clinical assessment
(gait/cognition/incontinence),NA,Acetazolamide,Baseline vs
post-drug,Clinical improvement
(gait/cognition/incontinence),Ordinal,Chronic,Patients with
NPH,NR,NR,Letter to the Editor; no ICP/CSF data;
uncontrolled,PIIS014067369712390X.pdf

Vates_1964_AmJPhysiol,Vates_1964_AmJPhysiol,Vates,1964,Am J
Physiol,\"Vates TS Jr, Bonting SL, Oppelt WW. Na-K activated adenosine
triphosphatase and formation of cerebrospinal fluid in the cat. Am J
Physiol. 1964;206:1165-1172\",NR,Cat,USA,Animal model,NA,NR,\"NA
(healthy animals)\",No,Experimental animal,Ventriculo-cisternal
perfusion in cats to measure CSF formation rate and effects of
inhibitors (ouabain, acetazolamide).,Ventriculo-cisternal perfusion
(inulin dilution),Ventricular,Acetazolamide,Baseline vs post-ACZ,CSF
formation rate,Continuous,Acute (during perfusion),Cats (2.1-4.1
kg),NA,NIH,Animal study; focus on ouabain,jphysiol01358-0114.pdf

Gucer_1978_JNeurosurg,Gucer_1978_JNeurosurg,Gücer,1978,J
Neurosurg,\"Gücer G, Viernstein L. Long-term intracranial pressure
recording in the management of pseudotumor cerebri. J Neurosurg.
1978;49(2):256-263\",NR,Human,USA,IIH/PTCS,Adults,4,Pseudotumor
cerebri,Yes,Case series,Long-term ICP monitoring (implanted sensor) to
manage 4 PTCS patients with Diamox, steroids, or shunting.,Implanted
pressure sensor,Parenchymal (implanted sensor),Acetazolamide
(Diamox),Baseline vs post-drug (ACZ or Steroids or Shunt),Change in ICP;
ICP stabilization,Continuous,Chronic (days to months),Patients with
pseudotumor cerebri,NR,NIH (subcontract),Very small N (4
cases),10.3171@jns.1978.49.2.0256.pdf

Rivas_1983_IntracranialPressureV,Rivas_1983_IntracranialPressureV,Rivas,1983,Intracranial
Pressure V,\"Rivas JJ, Lobato RD, Muñoz JM, et al. Effect of
Acetazolamide and Dexamethasone on the Cerebrospinal Fluid Pressure in
Patients with Pseudotumor Cerebri. In: Ishii S, Nagai H, Brock M, eds.
Intracranial Pressure V. Springer Berlin Heidelberg;
1983:763-767\",NR,Human,Spain,IIH/PTCS,Mixed,40,idiopathic pseudotumor
cerebri,Yes,Prospective cohort (uncontrolled),Analysis of ICP changes in
40 PTCS patients in response to acetazolamide and/or
dexamethasone.,Continuous CSF pressure recording,Lumbar (21) or
Intracranial (19),Acetazolamide (Diamox),Baseline vs ACZ vs
Dexamethasone,Change in CSF pressure,Continuous,Acute (hours) and
Chronic (years),Patients with symptoms/signs of IH, raised CSF pressure,
normal neuro studies/CSF,NR,NR,Uncontrolled; mixed measurement sites;
grouped analysis based on response,978-3-642-69204-8_132.pdf

Sorensen_1988_ActaNeurolScand,Sorensen_1988_ActaNeurolScand,Sørensen,1988,Acta
Neurol Scand,\"Sørensen PS, Krogsaa B, Gjerris F. Clinical course and
prognosis of pseudotumor cerebri. A prospective study of 24 patients.
Acta Neurol Scand.
1988;77(2):164-172\",10.1111/j.1600-0404.1988.tb05888.x,Human,Denmark,IIH/PTCS,Mixed
(13-66 yrs),24,Pseudotumor cerebri,Yes,Prospective cohort,Prospective
follow-up (avg 49 mos) of 24 PTCS patients treated with diuretics and
acetazolamide.,Epidural transducer or lumbar
cannula,Epidural/Lumbar,Acetazolamide,\"Baseline vs post-drug
(long-term)\",Clinical symptoms, ophthalmologic signs, ICP,Continuous /
Ordinal,Chronic (6-18 months treatment),Diagnostic criteria for
pseudotumor cerebri (ICP \> 18 mm Hg, papilledema, etc.),Venous sinus
thrombosis,NR,Prospective, long follow-up; not all received ACZ
(17/24),10.1111@j.1600-0404.1988.tb05888.x.pdf

Liu_1994_JNeurosurg,Liu_1994_JNeurosurg,Liu,1994,J Neurosurg,\"Liu K,
Kuether TA, Gowing L, Adelson PD, Tunturi R. Intraoperative intracranial
pressure monitoring in patients with pseudotumor cerebri. J Neurosurg.
1994;81(5):798-801\",NR,Human,USA,IIH/PTCS,Mixed
(Adults/Children),7,\"Pseudotumor cerebri\",Yes,Case
series,Intraoperative ICP monitoring via subdural catheter in 7 PTCS
patients, 3 received IV acetazolamide.,Subdural ICP catheter,Parenchymal
(Subdural),Acetazolamide,Baseline vs post-ACZ (acute intraop),Change in
ICP,Continuous,Intraoperative (minutes),Patients with pseudotumor
cerebri undergoing neuro-op procedures,NR,NR,Very small N (3/7 received
ACZ); intraoperative setting,liu1994.pdf

Code snippet

STUDY_ID,PARENT_TRIAL_ID,CONDITION_ID,CONDITION_LABEL_AS_REPORTED,CONDITION_TYPE,N_SUBJECTS_IN_CONDITION,CAI_PRESENT,CAI_DRUG_NAME,CAI_REGIMEN_TEXT,CAI_EXPOSURE_CATEGORY,OTHER_DRUGS_TEXT,CSF_DRAINAGE_STATUS_TEXT,POSITION_SEDATION_TEXT,CONDITION_NOTES

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ACZ_Chronic,ACZ,Chronic_CAI,8,Yes,Acetazolamide,\"125
mg/day, increased to max 375 mg/day over 3 months\",Chronic,None,No
drainage,NR,Off-label treatment

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ELD_Acute,ELD,Drainage_Only,12,No,None,NA,None,None,External
lumbar drainage for up to 72 hours,NR,NR

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,Control,Controls,Baseline,5,No,None,NA,None,None,No
drainage,NR,\"Clinically-stable iNPH, no intervention\"

Birzis_1958_Neurology,Birzis_1958_Neurology,Baseline,Control,Baseline,10,No,None,NA,None,None,No
drainage,NR,NR

Birzis_1958_Neurology,Birzis_1958_Neurology,ACZ_Acute,Acetazolamide,Acute_CAI,10,Yes,Acetazolamide,50
mg/kg IV or IM (single dose),SingleDose,None,No drainage,NR,NR

Schoeman_1994_JChildNeurol,Schoeman_1994_JChildNeurol,Standard_Only,Standard
therapy,OtherDrug_Only,18,No,None,NA,None,\"Standard TB therapy
(isoniazid, rifampin, pyrazinamide) + prednisolone\",No drainage,NR,NR

Schoeman_1994_JChildNeurol,Schoeman_1994_JChildNeurol,Standard_plus_Diuretics,Standard
therapy +
diuretics,Combined_CAI_OtherDrug,18,Yes,Acetazolamide,\"Acetazolamide
100 mg/kg/day (oral) + Furosemide 1 mg/kg/day
(oral)\",Chronic,\"Furosemide + Standard TB therapy + prednisolone\",No
drainage,NR,Diuretics given for 1 month

Schain_1969_AmJDisChild,Schain_1969_AmJDisChild,ACZ_Chronic,Acetazolamide,Chronic_CAI,12,Yes,Acetazolamide,40-100
mg/kg/day (oral),Chronic,None,No drainage,NR,NR

Schain_1969_AmJDisChild,Schain_1969_AmJDisChild,OtherCAI_Chronic,Other
CAI,Chronic_CAI,4,Yes,Methazolamide or Ethoxzolamide,NR,Chronic,None,No
drainage,NR,NR

Huttenlocher_1965_JPediatr,Huttenlocher_1965_JPediatr,ACZ_Chronic,Acetazolamide,Chronic_CAI,15,Yes,Acetazolamide,50-100
mg/kg/day (oral),Chronic,None,No drainage,NR,NR

Silverberg_1998_Lancet,Silverberg_1998_Lancet,ACZ_plus_Furosemide_Chronic,Acetazolamide +
Furosemide,Combined_CAI_OtherDrug,12,Yes,Acetazolamide,Acetazolamide
125-250 mg PO tid + Furosemide 40 mg PO qd,Chronic,Furosemide,No
drainage,NR,NR

Vates_1964_AmJPhysiol,Vates_1964_AmJPhysiol,Baseline,Control,Baseline,7,No,None,NA,None,None,Ventriculo-cisternal
perfusion,\"Anesthetized, ventilated\",Control period of perfusion

Vates_1964_AmJPhysiol,Vates_1964_AmJPhysiol,ACZ_Acute,Acetazolamide,Acute_CAI,7,Yes,Acetazolamide,50
mg/kg IV (single dose),SingleDose,None,Ventriculo-cisternal
perfusion,\"Anesthetized, ventilated\",Drug added to perfusion

Gucer_1978_JNeurosurg,Gucer_1978_JNeurosurg,Baseline,Baseline
(pre-treatment),Baseline,4,No,None,NA,None,None,No drainage,NR,NR

Gucer_1978_JNeurosurg,Gucer_1978_JNeurosurg,ACZ_Chronic,Diamox,Chronic_CAI,2,Yes,Acetazolamide,4
gm/day,Chronic,None,No drainage,NR,\"Used in Case 2 (after shunt
removal) and Case 3\"

Gucer_1978_JNeurosurg,Gucer_1978_JNeurosurg,Steroids_Chronic,Steroids,OtherDrug_Only,4,No,None,NR,Chronic,Steroids
(dexamethasone, prednisone),No drainage,NR,Used in all 4 patients at
various times

Gucer_1978_JNeurosurg,Gucer_1978_JNeurosurg,Shunt,Thecoperitoneal
shunt,NA,3,No,None,NA,NA,None,Thecoperitoneal shunt,NR,Cases 1, 2, 4

Rivas_1983_IntracranialPressureV,Rivas_1983_IntracranialPressureV,Baseline,Basal
conditions,Baseline,40,No,None,NA,None,None,No drainage,NR,NR

Rivas_1983_IntracranialPressureV,Rivas_1983_IntracranialPressureV,ACZ_Acute,Diamox,Acute_CAI,40,Yes,Acetazolamide,500
to 3000 mg/day,Acute_CAI,None,No drainage,NR,\"Dose range reported,
effect measured acutely (hours)\"

Rivas_1983_IntracranialPressureV,Rivas_1983_IntracranialPressureV,DEX_Acute,Dexamethasone,OtherDrug_Only,40,No,None,8
to 32 mg/day,Acute_CAI,Dexamethasone,No drainage,NR,\"Dose range
reported, effect measured acutely (hours)\"

Rivas_1983_IntracranialPressureV,Rivas_1983_IntracranialPressureV,ACZplusDEX_Acute,Both
agents,Combined_CAI_OtherDrug,NR,Yes,Acetazolamide,\"e.g., Acetazolamide
2000 mg/day + Dexamethasone 16 mg/day\",Acute_CAI,Dexamethasone,No
drainage,NR,Example from Fig 1/2

Sorensen_1988_ActaNeurolScand,Sorensen_1988_ActaNeurolScand,Baseline,Baseline,Baseline,24,No,None,NA,None,None,No
drainage,NR,ICP measured at baseline

Sorensen_1988_ActaNeurolScand,Sorensen_1988_ActaNeurolScand,ACZ_plus_Diuretic_Chronic,Standard
treatment (ACZ +
Diuretics),Combined_CAI_OtherDrug,17,Yes,Acetazolamide,Acetazolamide
750-1500 mg daily for 6-18 months,Chronic,\"Diuretics (furosemide 80 mg
or chlorthalidone 100 mg daily)\",No drainage,NR,NR

Sorensen_1988_ActaNeurolScand,Sorensen_1988_ActaNeurolScand,Diuretic_Only_Chronic,Standard
treatment (Diuretics only),OtherDrug_Only,7,No,None,NA,None,\"Diuretics
(furosemide 80 mg or chlorthalidone 100 mg daily)\",No drainage,NR,NR

Sorensen_1988_ActaNeurolScand,Sorensen_1988_ActaNeurolScand,Shunt,Shunt,NA,5,NA,NA,NA,NA,NA,Ventriculo-peritoneal
shunt,NA,Required shunt operation

Liu_1994_JNeurosurg,Liu_1994_JNeurosurg,Baseline,Baseline
(intraoperative),Baseline,3,No,None,NA,None,None,No drainage,\"Supine,
general anesthesia\",ICP monitoring on 3/7 patients who received ACZ

Liu_1994_JNeurosurg,Liu_1994_JNeurosurg,ACZ_Acute,Acetazolamide
(intraoperative),Acute_CAI,3,Yes,Acetazolamide,1 g IV (single
bolus),SingleDose,None,No drainage,\"Supine, general anesthesia\",NR

Code snippet

STUDY_ID,PARENT_TRIAL_ID,ROW_TYPE,CONDITION_ID,CONDITION_ID_REFERENCE,CONDITION_ID_EXPERIMENTAL,MEASUREMENT_DOMAIN,MEASUREMENT_NAME_STANDARDIZED,MEASUREMENT_NAME_AS_REPORTED,MEASUREMENT_DEFINITION_TEXT,TIMEPOINT_OR_WINDOW_TEXT,CENTRAL_TENDENCY_TYPE,CENTRAL_VALUE,SPREAD_TYPE,SPREAD_VALUE_1,SPREAD_VALUE_2,N_MEASURED,EFFECT_MEASURE_TYPE,EFFECT_VALUE,EFFECT_CI_LOWER,EFFECT_CI_UPPER,EFFECT_P_VALUE,UNITS,MEASUREMENT_SOURCE_LOCATION,MEASUREMENT_NOTES

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ContrastEffect,NA,Control,ACZ_Chronic,Imaging,T1_Hypointensity_Volume,Decrease
in T1 hypo-intensities (ACZ Improvement),Automated FreeSurfer,3
months,Mean,4651,SE,2909,NA,7,MD,4651,NR,NR,0.002,mm3,Fig 1 / Table
1,Value for 7 responders vs 5 controls

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ContrastEffect,NA,Control,ACZ_Chronic,Imaging,DTI_MD,MD
decrease within T1 hypo-intensities (ACZ Improvement),DTI MD in
T1-hypo,3
months,Mean,7.9,SE,2.96,NA,7,PercentChange,7.9,NR,NR,0.0002,%,Fig 1 /
Table 1,Value for 7 responders vs 5 controls

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ContrastEffect,NA,Baseline,ACZ_Chronic,Imaging,CBF_WholeBrain,Symmetrized
% change CBF (ACZ Responders),ASL perfusion,3
months,Mean,18.8,SE,8.7,NA,6,PercentChange,18.8,NR,NR,NR,%,Table 1,Value
for 6 responders

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ContrastEffect,NA,Baseline,ACZ_Chronic,Imaging,CBF_WholeBrain,Symmetrized
% change CBF (ACZ Non-Responder),ASL perfusion,3
months,Mean,-9.6,None,NA,NA,1,PercentChange,-9.6,NR,NR,NR,%,Table
1,Value for patient ACZ_6

Birzis_1958_Neurology,Birzis_1958_Neurology,ConditionValue,Baseline,NA,NA,ICP,VentricularPressure,Initial
Pressure,Ventricular or lumbar
puncture,Baseline,Mean,302,Range,160,455,10,NA,NA,NA,NA,NR,mm H2O,Table
1,NR

Birzis_1958_Neurology,Birzis_1958_Neurology,ContrastEffect,NA,Baseline,ACZ_Acute,ICP,VentricularPressure,Drop
in Pressure,Ventricular or lumbar puncture,2-6 hours
post-dose,Mean,-102,Range,-40,-210,10,MD,-102,NR,NR,\<0.01,mm H2O,Table
1,NR

Birzis_1958_Neurology,Birzis_1958_Neurology,ConditionValue,Baseline,NA,NA,Electrolytes,CSF_HCO3,CSF
Bicarbonate,NR,Baseline,Mean,22.3,SE,0.7,10,NA,NA,NA,NA,NR,mEq/L,Table
2,NR

Birzis_1958_Neurology,Birzis_1958_Neurology,ConditionValue,ACZ_Acute,NA,NA,Electrolytes,CSF_HCO3,CSF
Bicarbonate,NR,4-6 hours
post-dose,Mean,17.8,SE,0.9,10,NA,NA,NA,NA,NR,mEq/L,Table 2,NR

Birzis_1958_Neurology,Birzis_1958_Neurology,ConditionValue,Baseline,NA,NA,Electrolytes,CSF_Cl,CSF
Chloride,NR,Baseline,Mean,122,SE,1.4,10,NA,NA,NA,NA,NR,mEq/L,Table 2,NR

Birzis_1958_Neurology,Birzis_1958_Neurology,ConditionValue,ACZ_Acute,NA,NA,Electrolytes,CSF_Cl,CSF
Chloride,NR,4-6 hours
post-dose,Mean,128,SE,1.3,10,NA,NA,NA,NA,NR,mEq/L,Table 2,NR

Birzis_1958_Neurology,Birzis_1958_Neurology,ConditionValue,Baseline,NA,NA,Electrolytes,Serum_HCO3,Serum
Bicarbonate,NR,Baseline,Mean,22.8,SE,1.1,10,NA,NA,NA,NA,NR,mEq/L,Table
2,NR

Birzis_1958_Neurology,Birzis_1958_Neurology,ConditionValue,ACZ_Acute,NA,NA,Electrolytes,Serum_HCO3,Serum
Bicarbonate,NR,4-6 hours
post-dose,Mean,18.9,SE,1.2,10,NA,NA,NA,NA,NR,mEq/L,Table 2,NR

Schoeman_1994_JChildNeurol,Schoeman_1994_JChildNeurol,ConditionValue,Standard_Only,NA,NA,ICP,ICP_Mean,Mean
ICP,Epidural ICP monitoring,Day 1-7
(pooled),Mean,26.9,SD,8.9,NA,18,NA,NA,NA,NA,NR,mm Hg,Table 1,NR

Schoeman_1994_JChildNeurol,Schoeman_1994_JChildNeurol,ConditionValue,Standard_plus_Diuretics,NA,NA,ICP,ICP_Mean,Mean
ICP,Epidural ICP monitoring,Day 1-7
(pooled),Mean,17.6,SD,3.5,NA,18,NA,NA,NA,NA,NR,mm Hg,Table 1,NR

Schoeman_1994_JChildNeurol,Schoeman_1994_JChildNeurol,ContrastEffect,NA,Standard_Only,Standard_plus_Diuretics,ICP,ICP_Mean,Mean
ICP,Epidural ICP monitoring,Day 1-7
(pooled),NR,NA,NR,NA,NA,NR,MD,-9.3,NR,NR,\<0.01,mm Hg,Table 1 / text p.
149,Calculated difference of means

Schain_1969_AmJDisChild,Schain_1969_AmJDisChild,ConditionValue,ACZ_Chronic,NA,NA,Clinical,ClinicalOutcome_Arrest,Response
to acetazolamide (Arrest),Arrest of head
enlargement,Chronic,CountOnly,5,None,NA,NA,12,NA,NA,NA,NA,NR,NA,text p.
622,NR

Schain_1969_AmJDisChild,Schain_1969_AmJDisChild,ConditionValue,ACZ_Chronic,NA,NA,Clinical,ClinicalOutcome_Slowing,Response
to acetazolamide (Slowing),Slowing of head
enlargement,Chronic,CountOnly,4,None,NA,NA,12,NA,NA,NA,NA,NR,NA,text p.
622,NR

Schain_1969_AmJDisChild,Schain_1969_AmJDisChild,ConditionValue,ACZ_Chronic,NA,NA,Clinical,ClinicalOutcome_Failure,Response
to acetazolamide
(Failure),Failure,Chronic,CountOnly,3,None,NA,NA,12,NA,NA,NA,NA,NR,NA,text
p. 622,NR

Huttenlocher_1965_JPediatr,Huttenlocher_1965_JPediatr,ConditionValue,ACZ_Chronic,NA,NA,Clinical,ClinicalOutcome_Arrest,Response
to acetazolamide (Arrest),Arrest of
hydrocephalus,Chronic,CountOnly,7,None,NA,NA,15,NA,NA,NA,NA,NR,NA,\"Table
I, text p. 1024\",NR

Huttenlocher_1965_JPediatr,Huttenlocher_1965_JPediatr,ConditionValue,ACZ_Chronic,NA,NA,Clinical,ClinicalOutcome_TemporaryArrest,Response
to acetazolamide (Temporary arrest),Temporary arrest (2-6
mos),Chronic,CountOnly,3,None,NA,NA,15,NA,NA,NA,NA,NR,NA,\"Table I, text
p. 1024\",NR

Huttenlocher_1965_JPediatr,Huttenlocher_1965_JPediatr,ConditionValue,ACZ_Chronic,NA,NA,Clinical,ClinicalOutcome_Failure,Response
to acetazolamide
(Failure),Failure,Chronic,CountOnly,5,None,NA,NA,15,NA,NA,NA,NA,NR,NA,\"Table
I, text p. 1024\",NR

Silverberg_1998_Lancet,Silverberg_1998_Lancet,ConditionValue,ACZ_plus_Furosemide_Chronic,NA,NA,Clinical,ClinicalOutcome_Improvement,Improvement,Clinical
improvement (gait, cognition,
continence),Chronic,CountOnly,9,None,NA,NA,12,NA,NA,NA,NA,NR,NA,text p.
216,NR

Vates_1964_AmJPhysiol,Vates_1964_AmJPhysiol,ConditionValue,Baseline,NA,NA,CSF_Production,CSF_FormationRate,CSF
formation rate,Ventriculo-cisternal perfusion, inulin dilution,Control
period,Mean,0.019,SE,0.001,NA,7,NA,NA,NA,NA,NR,ml/min,Table 1,NR

Vates_1964_AmJPhysiol,Vates_1964_AmJPhysiol,ConditionValue,ACZ_Acute,NA,NA,CSF_Production,CSF_FormationRate,CSF
formation rate,V-C perfusion,After Acetazolamide 50
mg/kg,Mean,0.010,SE,0.001,NA,7,NA,NA,NA,NA,NR,ml/min,Table 1,NR

Vates_1964_AmJPhysiol,Vates_1964_AmJPhysiol,ContrastEffect,NA,Baseline,ACZ_Acute,CSF_Production,CSF_FormationRate,Inhibition
of CSF formation,V-C perfusion,After Acetazolamide 50
mg/kg,NR,NA,NR,NA,NA,7,PercentChange,-47.4,NR,NR,\<0.01,%,Table 1,NR

Gucer_1978_JNeurosurg,Gucer_1978_JNeurosurg,ConditionValue,Baseline,NA,NA,ICP,ICP_Mean,Intracranial
pressure (Case 1),Implanted sensor,Baseline (Case
1),Range,NR,Range,50,400,1,NA,NA,NA,NA,NR,mm H2O,Fig 3,Graphical
representation

Gucer_1978_JNeurosurg,Gucer_1978_JNeurosurg,ConditionValue,Baseline,NA,NA,ICP,ICP_Mean,Intracranial
pressure (Case 2),Implanted sensor,Baseline (Case
2),Range,NR,Range,150,525,1,NA,NA,NA,NA,NR,mm H2O,Fig 5,Graphical
representation

Gucer_1978_JNeurosurg,Gucer_1978_JNeurosurg,ConditionValue,ACZ_Chronic,NA,NA,ICP,ICP_Mean,Pressure
(Case 2),Implanted sensor,Chronic Diamox
tx,Mean,200,NR,NA,NA,1,NA,NA,NA,NA,NR,mm H2O,Fig 6 / text p.
259,Approximated from graph

Gucer_1978_JNeurosurg,Gucer_1978_JNeurosurg,ConditionValue,Baseline,NA,NA,ICP,ICP_Mean,Pressure
sensor (Case 3),Implanted sensor,Baseline (Case 3,
recurrence),Mean,400,NR,NA,NA,1,NA,NA,NA,NA,NR,mm H2O,text p. 261,NR

Gucer_1978_JNeurosurg,Gucer_1978_JNeurosurg,ConditionValue,ACZ_Chronic,NA,NA,ICP,ICP_Mean,Pressure
(Case 3),Implanted sensor,12 hours
post-Diamox,Mean,210,NR,NA,NA,1,NA,NA,NA,NA,NR,mm H2O,Fig 7,Approximated
from graph

Rivas_1983_IntracranialPressureV,Rivas_1983_IntracranialPressureV,ConditionValue,Baseline,NA,NA,ICP,ICP_Mean,Mean
CSF pressure (Group
I),Lumbar/Intracranial,Baseline,Range,NR,Range,14,57,18,NA,NA,NA,NA,NR,mm
Hg,text p. 764,NR

Rivas_1983_IntracranialPressureV,Rivas_1983_IntracranialPressureV,ConditionValue,Baseline,NA,NA,ICP,ICP_Mean,Mean
CSF pressure (Group
II),Lumbar/Intracranial,Baseline,Range,NR,Range,14,52,15,NA,NA,NA,NA,NR,mm
Hg,text p. 764,NR

Rivas_1983_IntracranialPressureV,Rivas_1983_IntracranialPressureV,ContrastEffect,NA,Baseline,ACZ_Acute,ICP,ICP_Mean,Total
reductions (Group I),Lumbar/Intracranial,Within
hours,Range,NR,Range,-58,-96,18,PercentChange,NR,NR,NR,NR,%,text p.
764,\"Range of % reductions\"

Rivas_1983_IntracranialPressureV,Rivas_1983_IntracranialPressureV,ContrastEffect,NA,Baseline,DEX_Acute,ICP,ICP_Mean,Total
reductions (Group I),Lumbar/Intracranial,Within
hours,Range,NR,Range,-58,-96,18,PercentChange,NR,NR,NR,NR,%,text p.
764,\"Range of % reductions\"

Rivas_1983_IntracranialPressureV,Rivas_1983_IntracranialPressureV,ContrastEffect,NA,Baseline,ACZ_Acute,ICP,ICP_Mean,Total
reductions (Group II),Lumbar/Intracranial,Within
hours,Range,NR,Range,-7,-66,15,PercentChange,NR,NR,NR,NR,%,text p.
764,\"Range of % reductions\"

Rivas_1983_IntracranialPressureV,Rivas_1983_IntracranialPressureV,ContrastEffect,NA,Baseline,DEX_Acute,ICP,ICP_Mean,Total
reductions (Group II),Lumbar/Intracranial,Within
hours,Range,NR,Range,-7,-66,15,PercentChange,NR,NR,NR,NR,%,text p.
764,\"Range of % reductions\"

Rivas_1983_IntracranialPressureV,Rivas_1983_IntracranialPressureV,ConditionValue,Baseline,NA,NA,ICP,ICP_Mean,Histogram
(Basal),Intraventricular,Basal
conditions,Mean,55,NR,NA,NA,1,NA,NA,NA,NA,NR,mmHg,Fig 2.A,Approximated
mean from histogram

Rivas_1983_IntracranialPressureV,Rivas_1983_IntracranialPressureV,ConditionValue,ACZ_Acute,NA,NA,ICP,ICP_Mean,Histogram
(Acetazolamide),Intraventricular,After acetazolamide (2000
mg/day),Mean,38,NR,NA,NA,1,NA,NA,NA,NA,NR,mmHg,Fig 2.B,Approximated mean
from histogram

Rivas_1983_IntracranialPressureV,Rivas_1983_IntracranialPressureV,ConditionValue,DEX_Acute,NA,NA,ICP,ICP_Mean,Histogram
(Dexamethasone),Intraventricular,After dexamethasone (16
mg/day),Mean,25,NR,NA,NA,1,NA,NA,NA,NA,NR,mmHg,Fig 2.C,Approximated mean
from histogram

Rivas_1983_IntracranialPressureV,Rivas_1983_IntracranialPressureV,ConditionValue,ACZplusDEX_Acute,NA,NA,ICP,ICP_Mean,Histogram
(Both),Intraventricular,After both
agents,Mean,18,NR,NA,NA,1,NA,NA,NA,NA,NR,mmHg,Fig 2.D,Approximated mean
from histogram

Sorensen_1988_ActaNeurolScand,Sorensen_1988_ActaNeurolScand,ConditionValue,Baseline,NA,NA,ICP,ICP_Mean,Steady
state mean intracranial pressure,Epidural (16) or lumbar (8),Baseline
(admission),Median,25,Range,8,45,24,NA,NA,NA,NA,NR,mm Hg,text p. 166,1
patient had 8 mmHg, all others \>=18 mmHg

Sorensen_1988_ActaNeurolScand,Sorensen_1988_ActaNeurolScand,ConditionValue,Baseline,NA,NA,ICP,CSF_OutflowConductance,Conductance
to CSF outflow (Cout),Lumbo-lumbar perfusion,Baseline
(admission),NR,NR,None,NA,NA,24,NA,NA,NA,NA,NR,ml.mm Hg-1.min-1,text p.
166,\"Reported as \"\"below normal \<0.080\"\" in all\"

Sorensen_1988_ActaNeurolScand,Sorensen_1988_ActaNeurolScand,ConditionValue,Baseline,NA,NA,ICP,ICP_PlateauWaves,Plateau
waves,Epidural/lumbar monitoring,Baseline
(admission),CountOnly,8,None,NA,NA,24,NA,NA,NA,NA,NR,NA,text p. 166,Peak
pressure up to 70 mm Hg

Sorensen_1988_ActaNeurolScand,Sorensen_1988_ActaNeurolScand,ConditionValue,ACZ_plus_Diuretic_Chronic,NA,NA,ICP,ICP_Mean,ICP
(After),Lumbar pressure monitoring,12-48 months
post-baseline,Mean,11.4,SD,8.2,NA,10,NA,NA,NA,NA,NR,mm Hg,Table
2,Calculated from N=10 \'After\' values

Sorensen_1988_ActaNeurolScand,Sorensen_1988_ActaNeurolScand,ConditionValue,ACZ_plus_Diuretic_Chronic,NA,NA,ICP,CSF_OutflowConductance,Cout
(After),Lumbo-lumbar perfusion,12-48 months
post-baseline,Mean,0.058,SD,0.02,NA,10,NA,NA,NA,NA,NR,ml.mm
Hg-1.min-1,Table 2,Calculated from N=10 \'After\' values

Liu_1994_JNeurosurg,Liu_1994_JNeurosurg,ConditionValue,Baseline,NA,NA,ICP,ICP_Mean,Baseline
ICP,Subdural catheter,Intraop
baseline,Mean,30,Range,24,38,3,NA,NA,NA,NA,NR,mm Hg,text p. 799,Data for
the 3 patients who received ACZ

Liu_1994_JNeurosurg,Liu_1994_JNeurosurg,ContrastEffect,NA,Baseline,ACZ_Acute,ICP,ICP_Mean,Reduction
in ICP,Subdural catheter,15-30 min post-dose (1g
IV),Range,NR,Range,-33,-46,3,PercentChange,NR,NR,NR,NR,%,text p. 799,NR

Liu_1994_JNeurosurg,Liu_1994_JNeurosurg,ContrastEffect,NA,Baseline,ACZ_Acute,ICP,ICP_Mean,Reduction
in ICP,Subdural catheter,15-30 min post-dose (1g
IV),Range,NR,Range,-10,-14,3,MD,NR,NR,NR,NR,mm Hg,text p. 799,NR

Code snippet

STUDY_ID,PARENT_TRIAL_ID,CONDITION_ID,AE_NAME_STANDARDIZED,AE_NAME_AS_REPORTED,AE_CATEGORY_TEXT,AE_SEVERITY_CATEGORY_TEXT,EVENT_COUNT,N_AT_RISK,RELATED_TO_CAI_AS_REPORTED,AE_DEFINITION_TEXT,AE_SOURCE_LOCATION

Schain_1969_AmJDisChild,Schain_1969_AmJDisChild,ACZ_Chronic,MetabolicAcidosis,Chronic
acidosis,Metabolic,AnyGrade,NR,12,Yes,NR,text p. 624

Schain_1969_AmJDisChild,Schain_1969_AmJDisChild,ACZ_Chronic,GI_Symptoms,Anorexia,Gastrointestinal,AnyGrade,NR,12,Yes,NR,text
p. 624

Schain_1969_AmJDisChild,Schain_1969_AmJDisChild,ACZ_Chronic,GI_Symptoms,Vomiting,Gastrointestinal,AnyGrade,NR,12,Yes,NR,text
p. 624

Schain_1969_AmJDisChild,Schain_1969_AmJDisChild,ACZ_Chronic,Tachypnea,Tachypnea,Respiratory,AnyGrade,NR,12,Yes,NR,text
p. 624

Huttenlocher_1965_JPediatr,Huttenlocher_1965_JPediatr,ACZ_Chronic,MetabolicAcidosis,Metabolic
acidosis,Metabolic,AnyGrade,NR,15,Yes,\"CO2 content 10-15 mEq/L\",text
p. 1029

Huttenlocher_1965_JPediatr,Huttenlocher_1965_JPediatr,ACZ_Chronic,Hypokalemia,Hypokalemia,Electrolyte,AnyGrade,NR,15,Yes,NR,text
p. 1029

Huttenlocher_1965_JPediatr,Huttenlocher_1965_JPediatr,ACZ_Chronic,GI_Symptoms,Anorexia,Gastrointestinal,AnyGrade,NR,15,Yes,NR,text
p. 1029

Sorensen_1988_ActaNeurolScand,Sorensen_1988_ActaNeurolScand,ACZ_plus_Diuretic_Chronic,MetabolicAcidosis,Metabolic
acidosis,Metabolic,AnyGrade,NR,17,Yes,NR,text p. 166

Sorensen_1988_ActaNeurolScand,Sorensen_1988_ActaNeurolScand,ACZ_plus_Diuretic_Chronic,GI_Symptoms,Nausea,Gastrointestinal,AnyGrade,NR,17,Yes,NR,text
p. 166

Sorensen_1988_ActaNeurolScand,Sorensen_1988_ActaNeurolScand,ACZ_plus_Diuretic_Chronic,Paresthesia,\"Moderate
paresthesias in hands and feet\",Neurologic,AnyGrade,NR,17,Yes,NR,text
p. 166

Sorensen_1988_ActaNeurolScand,Sorensen_1988_ActaNeurolScand,ACZ_plus_Diuretic_Chronic,Psychiatric_Symptoms,Depression,Psychiatric,LeadingToDiscontinuation,1,17,Yes,Required
discontinuation of acetazolamide,text p. 167

Sorensen_1988_ActaNeurolScand,Sorensen_1988_ActaNeurolScand,Diuretic_Only_Chronic,Hypokalemia,Hypokalemia,Electrolyte,AnyGrade,NR,24,Yes
(to diuretics),All patients had potassium supplement,\"text p. 167,
Table 1\"

Sorensen_1988_ActaNeurolScand,Sorensen_1988_ActaNeurolScand,ACZ_plus_Diuretic_Chronic,Hypokalemia,Hypokalemia,Electrolyte,AnyGrade,NR,24,Yes
(to diuretics),All patients had potassium supplement,\"text p. 167,
Table 1\"

Code snippet

STUDY_ID,PARENT_TRIAL_ID,MODEL_ID,MODEL_TYPE,MODEL_OUTCOME_NAME_STANDARDIZED,MODEL_OUTCOME_NAME_AS_REPORTED,MODEL_OUTCOME_TYPE,PREDICTOR_NAME_STANDARDIZED,PREDICTOR_NAME_AS_REPORTED,PREDICTOR_CATEGORY,PREDICTOR_CODING_TEXT,EFFECT_MEASURE_TYPE,EFFECT_VALUE,EFFECT_CI_LOWER,EFFECT_CI_UPPER,EFFECT_P_VALUE,ADJUSTED_OR_UNADJUSTED,COVARIATES_ADJUSTED_FOR_TEXT,N_ANALYZED,MODEL_SOURCE_LOCATION

Code snippet

STUDY_ID,PARENT_TRIAL_ID,PATIENT_ID,CONDITION_ID,AGE_YEARS,SEX,VARIABLE_NAME_AS_REPORTED,VARIABLE_VALUE,VARIABLE_UNITS,IPD_SOURCE_LOCATION

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ACZ_1,Baseline,90,Male,Ventricle
vol. (Before),124758,mm3,Table 1

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ACZ_1,ACZ_Chronic,90,Male,Ventricle
vol. (After),125124,mm3,Table 1

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ACZ_1,Baseline,90,Male,T1
hypo. vol (Before),13653,mm3,Table 1

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ACZ_1,ACZ_Chronic,90,Male,T1
hypo. vol (After),12087,mm3,Table 1

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ACZ_1,Baseline,90,Male,CBF
(Before),13.2,ml/100ml/min,Table 1

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ACZ_1,ACZ_Chronic,90,Male,CBF
(After),NR,ml/100ml/min,Table 1

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ACZ_1,ACZ_Chronic,90,Male,Symmetrized
% change CBF,9.2,%,Table 1

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ACZ_2,Baseline,72,Female,Ventricle
vol. (Before),77447,mm3,Table 1

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ACZ_2,ACZ_Chronic,72,Female,Ventricle
vol. (After),76605,mm3,Table 1

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ACZ_2,Baseline,72,Female,T1
hypo. vol (Before),19073,mm3,Table 1

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ACZ_2,ACZ_Chronic,72,Female,T1
hypo. vol (After),11782,mm3,Table 1

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ACZ_2,Baseline,72,Female,CBF
(Before),25.9,ml/100ml/min,Table 1

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ACZ_2,ACZ_Chronic,72,Female,Symmetrized
% change CBF,8.5,%,Table 1

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ACZ_3,Baseline,86,Male,Ventricle
vol. (Before),123287,mm3,Table 1

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ACZ_3,ACZ_Chronic,86,Male,Ventricle
vol. (After),122220,mm3,Table 1

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ACZ_3,Baseline,86,Male,T1
hypo. vol (Before),16508,mm3,Table 1

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ACZ_3,ACZ_Chronic,86,Male,T1
hypo. vol (After),13891,mm3,Table 1

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ACZ_3,Baseline,86,Male,CBF
(Before),27.2,ml/100ml/min,Table 1

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ACZ_3,ACZ_Chronic,86,Male,Symmetrized
% change CBF,4.5,%,Table 1

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ACZ_4,Baseline,80,Female,Ventricle
vol. (Before),148137,mm3,Table 1

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ACZ_4,ACZ_Chronic,80,Female,Ventricle
vol. (After),146563,mm3,Table 1

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ACZ_4,Baseline,80,Female,T1
hypo. vol (Before),78730,mm3,Table 1

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ACZ_4,ACZ_Chronic,80,Female,T1
hypo. vol (After),70205,mm3,Table 1

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ACZ_4,Baseline,80,Female,CBF
(Before),17.2,ml/100ml/min,Table 1

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ACZ_4,ACZ_Chronic,80,Female,Symmetrized
% change CBF,3,%,Table 1

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ACZ_5,Baseline,76,Male,Ventricle
vol. (Before),165388,mm3,Table 1

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ACZ_5,ACZ_Chronic,76,Male,Ventricle
vol. (After),163105,mm3,Table 1

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ACZ_5,Baseline,76,Male,T1
hypo. vol (Before),13930,mm3,Table 1

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ACZ_5,ACZ_Chronic,76,Male,T1
hypo. vol (After),13196,mm3,Table 1

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ACZ_5,Baseline,76,Male,CBF
(Before),15.8,ml/100ml/min,Table 1

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ACZ_5,ACZ_Chronic,76,Male,Symmetrized
% change CBF,4.1,%,Table 1

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ACZ_6,Baseline,82,Female,Ventricle
vol. (Before),104325,mm3,Table 1

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ACZ_6,ACZ_Chronic,82,Female,Ventricle
vol. (After),105244,mm3,Table 1

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ACZ_6,Baseline,82,Female,T1
hypo. vol (Before),7714,mm3,Table 1

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ACZ_6,ACZ_Chronic,82,Female,T1
hypo. vol (After),8525,mm3,Table 1

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ACZ_6,Baseline,82,Female,CBF
(Before),33.7,ml/100ml/min,Table 1

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ACZ_6,ACZ_Chronic,82,Female,Symmetrized
% change CBF,-9.6,%,Table 1

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ACZ_7,Baseline,79,Male,Ventricle
vol. (Before),176078,mm3,Table 1

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ACZ_7,ACZ_Chronic,79,Male,Ventricle
vol. (After),176778,mm3,Table 1

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ACZ_7,Baseline,79,Male,T1
hypo. vol (Before),21785,mm3,Table 1

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ACZ_7,ACZ_Chronic,79,Male,T1
hypo. vol (After),14282,mm3,Table 1

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ACZ_7,Baseline,79,Male,CBF
(Before),16.8,ml/100ml/min,Table 1

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ACZ_7,ACZ_Chronic,79,Male,Symmetrized
% change CBF,19,%,Table 1

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ACZ_8,Baseline,79,Female,Ventricle
vol. (Before),111200,mm3,Table 1

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ACZ_8,ACZ_Chronic,79,Female,Ventricle
vol. (After),109500,mm3,Table 1

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ACZ_8,Baseline,79,Female,T1
hypo. vol (Before),23437,mm3,Table 1

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ACZ_8,ACZ_Chronic,79,Female,T1
hypo. vol (After),19114,mm3,Table 1

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ACZ_8,Baseline,79,Female,CBF
(Before),20.6,ml/100ml/min,Table 1

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ACZ_8,ACZ_Chronic,79,Female,Symmetrized
% change CBF,10.4,%,Table 1

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ELD_1,Baseline,70,Male,Ventricle
vol. (Before),282634,mm3,Table 3

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ELD_1,ELD_Acute,70,Male,Ventricle
vol. (After),252228,mm3,Table 3

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ELD_1,Baseline,70,Male,T1-hypo.
vol. (Before),18966,mm3,Table 3

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ELD_1,ELD_Acute,70,Male,T1-hypo.
vol. (After),21772,mm3,Table 3

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ELD_2,Baseline,76,Male,Ventricle
vol. (Before),222300,mm3,Table 3

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ELD_2,ELD_Acute,76,Male,Ventricle
vol. (After),189744,mm3,Table 3

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ELD_2,Baseline,76,Male,T1-hypo.
vol. (Before),34730,mm3,Table 3

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ELD_2,ELD_Acute,76,Male,T1-hypo.
vol. (After),37581,mm3,Table 3

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ELD_3,Baseline,75,Male,Ventricle
vol. (Before),89100,mm3,Table 3

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ELD_3,ELD_Acute,75,Male,Ventricle
vol. (After),54547,mm3,Table 3

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ELD_3,Baseline,75,Male,T1-hypo.
vol. (Before),9921,mm3,Table 3

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ELD_3,ELD_Acute,75,Male,T1-hypo.
vol. (After),5896,mm3,Table 3

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ELD_4,Baseline,65,Male,Ventricle
vol. (Before),165969,mm3,Table 3

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ELD_4,ELD_Acute,65,Male,Ventricle
vol. (After),159925,mm3,Table 3

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ELD_4,Baseline,65,Male,T1-hypo.
vol. (Before),27415,mm3,Table 3

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ELD_4,ELD_Acute,65,Male,T1-hypo.
vol. (After),25348,mm3,Table 3

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ELD_5,Baseline,74,Female,Ventricle
vol. (Before),120182,mm3,Table 3

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ELD_5,ELD_Acute,74,Female,Ventricle
vol. (After),129471,mm3,Table 3

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ELD_5,Baseline,74,Female,T1-hypo.
vol. (Before),15244,mm3,Table 3

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ELD_5,ELD_Acute,74,Female,T1-hypo.
vol. (After),17427,mm3,Table 3

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ELD_6,Baseline,76,Male,Ventricle
vol. (Before),106816,mm3,Table 3

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ELD_6,ELD_Acute,76,Male,Ventricle
vol. (After),112852,mm3,Table 3

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ELD_6,Baseline,76,Male,T1-hypo.
vol. (Before),6692,mm3,Table 3

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ELD_6,ELD_Acute,76,Male,T1-hypo.
vol. (After),6732,mm3,Table 3

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ELD_7,Baseline,73,Female,Ventricle
vol. (Before),155040,mm3,Table 3

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ELD_7,ELD_Acute,73,Female,Ventricle
vol. (After),162758,mm3,Table 3

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ELD_7,Baseline,73,Female,T1-hypo.
vol. (Before),15975,mm3,Table 3

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ELD_7,ELD_Acute,73,Female,T1-hypo.
vol. (After),18451,mm3,Table 3

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ELD_8,Baseline,70,Male,Ventricle
vol. (Before),104376,mm3,Table 3

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ELD_8,ELD_Acute,70,Male,Ventricle
vol. (After),103008,mm3,Table 3

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ELD_8,Baseline,70,Male,T1-hypo.
vol. (Before),19693,mm3,Table 3

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ELD_8,ELD_Acute,70,Male,T1-hypo.
vol. (After),18061,mm3,Table 3

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ELD_9,Baseline,76,Female,Ventricle
vol. (Before),74968,mm3,Table 3

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ELD_9,ELD_Acute,76,Female,Ventricle
vol. (After),73976,mm3,Table 3

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ELD_9,Baseline,76,Female,T1-hypo.
vol. (Before),7546,mm3,Table 3

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ELD_9,ELD_Acute,76,Female,T1-hypo.
vol. (After),6805,mm3,Table 3

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ELD_10,Baseline,73,Female,Ventricle
vol. (Before),54910,mm3,Table 3

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ELD_10,ELD_Acute,73,Female,Ventricle
vol. (After),55503,mm3,Table 3

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ELD_10,Baseline,73,Female,T1-hypo.
vol. (Before),4869,mm3,Table 3

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ELD_10,ELD_Acute,73,Female,T1-hypo.
vol. (After),4407,mm3,Table 3

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ELD_11,Baseline,70,Female,Ventricle
vol. (Before),104398,mm3,Table 3

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ELD_11,ELD_Acute,70,Female,Ventricle
vol. (After),98346,mm3,Table 3

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ELD_11,Baseline,70,Female,T1-hypo.
vol. (Before),29650,mm3,Table 3

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ELD_11,ELD_Acute,70,Female,T1-hypo.
vol. (After),30622,mm3,Table 3

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ELD_12,Baseline,83,Male,Ventricle
vol. (Before),135933,mm3,Table 3

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ELD_12,ELD_Acute,83,Male,Ventricle
vol. (After),143898,mm3,Table 3

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ELD_12,Baseline,83,Male,T1-hypo.
vol. (Before),14253,mm3,Table 3

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,ELD_12,ELD_Acute,83,Male,T1-hypo.
vol. (After),15896,mm3,Table 3

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,NON_1,Baseline,77,Male,Ventricle
vol. (Before),121128,mm3,Table 2

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,NON_1,Control,77,Male,Ventricle
vol. (After),124745,mm3,Table 2

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,NON_1,Baseline,77,Male,T1
hypo. vol (Before),15813,mm3,Table 2

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,NON_1,Control,77,Male,T1
hypo. vol (After),14142,mm3,Table 2

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,NON_2,Baseline,67,Female,Ventricle
vol. (Before),144100,mm3,Table 2

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,NON_2,Control,67,Female,Ventricle
vol. (After),147844,mm3,Table 2

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,NON_2,Baseline,67,Female,T1
hypo. vol (Before),30720,mm3,Table 2

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,NON_2,Control,67,Female,T1
hypo. vol (After),39721,mm3,Table 2

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,NON_3,Baseline,71,Male,Ventricle
vol. (Before),93459,mm3,Table 2

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,NON_3,Control,71,Male,Ventricle
vol. (After),99813,mm3,Table 2

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,NON_3,Baseline,71,Male,T1
hypo. vol (Before),13660,mm3,Table 2

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,NON_3,Control,71,Male,T1
hypo. vol (After),19765,mm3,Table 2

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,NON_4,Baseline,72,Female,Ventricle
vol. (Before),108616,mm3,Table 2

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,NON_4,Control,72,Female,Ventricle
vol. (After),111520,mm3,Table 2

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,NON_4,Baseline,72,Female,T1
hypo. vol (Before),10371,mm3,Table 2

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,NON_4,Control,72,Female,T1
hypo. vol (After),13991,mm3,Table 2

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,NON_5,Baseline,82,Male,Ventricle
vol. (Before),95869,mm3,Table 2

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,NON_5,Control,82,Male,Ventricle
vol. (After),99759,mm3,Table 2

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,NON_5,Baseline,82,Male,T1
hypo. vol (Before),11251,mm3,Table 2

Ivkovic_2015_FluidsBarriersCNS,Ivkovic_2015_FluidsBarriersCNS,NON_5,Control,82,Male,T1
hypo. vol (After),18639,mm3,Table 2

Birzis_1958_Neurology,Birzis_1958_Neurology,P01,Baseline,0.5,NR,Initial
Pressure,455,mm H2O,Table 1

Birzis_1958_Neurology,Birzis_1958_Neurology,P01,ACZ_Acute,0.5,NR,Pressure
after Diamox,245,mm H2O,Table 1

Birzis_1958_Neurology,Birzis_1958_Neurology,P02,Baseline,0.67,NR,Initial
Pressure,250,mm H2O,Table 1

Birzis_1958_Neurology,Birzis_1958_Neurology,P02,ACZ_Acute,0.67,NR,Pressure
after Diamox,150,mm H2O,Table 1

Birzis_1958_Neurology,Birzis_1958_Neurology,P03,Baseline,0.5,NR,Initial
Pressure,360,mm H2O,Table 1

Birzis_1958_Neurology,Birzis_1958_Neurology,P03,ACZ_Acute,0.5,NR,Pressure
after Diamox,150,mm H2O,Table 1

Birzis_1958_Neurology,Birzis_1958_Neurology,P04,Baseline,0.25,NR,Initial
Pressure,160,mm H2O,Table 1

Birzis_1958_Neurology,Birzis_1958_Neurology,P04,ACZ_Acute,0.25,NR,Pressure
after Diamox,120,mm H2O,Table 1

Birzis_1958_Neurology,Birzis_1958_Neurology,P05,Baseline,0.33,NR,Initial
Pressure,430,mm H2O,Table 1

Birzis_1958_Neurology,Birzis_1958_Neurology,P05,ACZ_Acute,0.33,NR,Pressure
after Diamox,305,mm H2O,Table 1

Birzis_1958_Neurology,Birzis_1958_Neurology,P06,Baseline,0.33,NR,Initial
Pressure,260,mm H2O,Table 1

Birzis_1958_Neurology,Birzis_1958_Neurology,P06,ACZ_Acute,0.33,NR,Pressure
after Diamox,180,mm H2O,Table 1

Birzis_1958_Neurology,Birzis_1958_Neurology,P07,Baseline,1.5,NR,Initial
Pressure,250,mm H2O,Table 1

Birzis_1958_Neurology,Birzis_1958_Neurology,P07,ACZ_Acute,1.5,NR,Pressure
after Diamox,200,mm H2O,Table 1

Birzis_1958_Neurology,Birzis_1958_Neurology,P08,Baseline,0.5,NR,Initial
Pressure,200,mm H2O,Table 1

Birzis_1958_Neurology,Birzis_1958_Neurology,P08,ACZ_Acute,0.5,NR,Pressure
after Diamox,140,mm H2O,Table 1

Birzis_1958_Neurology,Birzis_1True,P09,Baseline,0.5,NR,Initial
Pressure,170,mm H2O,Table 1

Birzis_1958_Neurology,Birzis_1958_Neurology,P09,ACZ_Acute,0.5,NR,Pressure
after Diamox,120,mm H2O,Table 1

Birzis_1958_Neurology,Birzis_1958_Neurology,P10,Baseline,8,NR,Initial
Pressure,490,mm H2O,Table 1

Birzis_1958_Neurology,Birzis_1958_Neurology,P10,ACZ_Acute,8,NR,Pressure
after Diamox,380,mm H2O,Table 1

Sorensen_1988_ActaNeurolScand,Sorensen_1988_ActaNeurolScand,P04,Baseline,43,Female,ICP
(Before),20,mm Hg,Table 2

Sorensen_1988_ActaNeurolScand,Sorensen_1988_ActaNeurolScand,P04,ACZ_plus_Diuretic_Chronic,43,Female,ICP
(After),10,mm Hg,Table 2

Sorensen_1988_ActaNeurolScand,Sorensen_1988_ActaNeurolScand,P04,Baseline,43,Female,Cout
(Before),0.041,ml.mm Hg-1.min-1,Table 2

Sorensen_1988_ActaNeurolScand,Sorensen_1988_ActaNeurolScand,P04,ACZ_plus_Diuretic_Chronic,43,Female,Cout
(After),0.073,ml.mm Hg-1.min-1,Table 2

Sorensen_1988_ActaNeurolScand,Sorensen_1988_ActaNeurolScand,P05,Baseline,38,Male,ICP
(Before),8,mm Hg,Table 2

Sorensen_1988_ActaNeurolScand,Sorensen_1988_ActaNeurolScand,P05,ACZ_plus_Diuretic_Chronic,38,Male,ICP
(After),8,mm Hg,Table 2

Sorensen_1988_ActaNeurolScand,Sorensen_1988_ActaNeurolScand,P05,Baseline,38,Male,Cout
(Before),0.073,ml.mm Hg-1.min-1,Table 2

Sorensen_1988_ActaNeurolScand,Sorensen_1988_ActaNeurolScand,P05,ACZ_plus_Diuretic_Chronic,38,Male,Cout
(After),NR,ml.mm Hg-1.min-1,Table 2

Sorensen_1988_ActaNeurolScand,Sorensen_1988_ActaNeurolScand,P10,Baseline,13,Male,ICP
(Before),18,mm Hg,Table 2

Sorensen_1988_ActaNeurolScand,Sorensen_1988_ActaNeurolScand,P10,Diuretic_Only_Chronic,13,Male,ICP
(After),8,mm Hg,Table 2

Sorensen_1988_ActaNeurolScand,Sorensen_1988_ActaNeurolScand,P10,Baseline,13,Male,Cout
(Before),0.140,ml.mm Hg-1.min-1,Table 2

Sorensen_1988_ActaNeurolScand,Sorensen_1988_ActaNeurolScand,P10,Diuretic_Only_Chronic,13,Male,Cout
(After),NR,ml.mm Hg-1.min-1,Table 2

Sorensen_1988_ActaNeurolScand,Sorensen_1988_ActaNeurolScand,P12,Baseline,36,Female,ICP
(Before),30,mm Hg,Table 2

Sorensen_1988_ActaNeurolScand,Sorensen_1988_ActaNeurolScand,P12,Shunt,36,Female,ICP
(After),5,mm Hg,Table 2

Sorensen_1988_ActaNeurolScand,Sorensen_1988_ActaNeurolScand,P12,Baseline,36,Female,Cout
(Before),0.036,ml.mm Hg-1.min-1,Table 2

Sorensen_1988_ActaNeurolScand,Sorensen_1988_ActaNeurolScand,P12,Shunt,36,Female,Cout
(After),0.036,ml.mm Hg-1.min-1,Table 2

Sorensen_1988_ActaNeurolScand,Sorensen_1988_ActaNeurolScand,P14,Baseline,15,Female,ICP
(Before),20,mm Hg,Table 2

Sorensen_1988_ActaNeurolScand,Sorensen_1988_ActaNeurolScand,P14,Shunt,15,Female,ICP
(After),1,mm Hg,Table 2

Sorensen_1988_ActaNeurolScand,Sorensen_1988_ActaNeurolScand,P14,Baseline,15,Female,Cout
(Before),0.046,ml.mm Hg-1.min-1,Table 2

Sorensen_1988_ActaNeurolScand,Sorensen_1988_ActaNeurolScand,P14,Shunt,15,Female,Cout
(After),NR,ml.mm Hg-1.min-1,Table 2

Sorensen_1988_ActaNeurolScand,Sorensen_1988_ActaNeurolScand,P15,Baseline,33,Female,ICP
(Before),35,mm Hg,Table 2

Sorensen_1988_ActaNeurolScand,Sorensen_1988_ActaNeurolScand,P15,ACZ_plus_Diuretic_Chronic,33,Female,ICP
(After),7,mm Hg,Table 2

Sorensen_1988_ActaNeurolScand,Sorensen_1988_ActaNeurolScand,P15,Baseline,33,Female,Cout
(Before),0.034,ml.mm Hg-1.min-1,Table 2

Sorensen_1988_ActaNeurolScand,Sorensen_1988_ActaNeurolScand,P15,ACZ_plus_Diuretic_Chronic,33,Female,Cout
(After),0.066,ml.mm Hg-1.min-1,Table 2

Sorensen_1988_ActaNeurolScand,Sorensen_1988_ActaNeurolScand,P16,Baseline,40,Male,ICP
(Before),20,mm Hg,Table 2

Sorensen_1988_ActaNeurolScand,Sorensen_1988_ActaNeurolScand,P16,Shunt,40,Male,ICP
(After),5,mm Hg,Table 2

Sorensen_1988_ActaNeurolScand,Sorensen_1988_ActaNeurolScand,P16,Baseline,40,Male,Cout
(Before),0.034,ml.mm Hg-1.min-1,Table 2

Sorensen_1988_ActaNeurolScand,Sorensen_1988_ActaNeurolScand,P16,Shunt,40,Male,Cout
(After),0.087,ml.mm Hg-1.min-1,Table 2

Sorensen_1988_ActaNeurolScand,Sorensen_1988_ActaNeurolScand,P21,Baseline,23,Female,ICP
(Before),25,mm Hg,Table 2

Sorensen_1988_ActaNeurolScand,Sorensen_1988_ActaNeurolScand,P21,ACZ_plus_Diuretic_Chronic,23,Female,ICP
(After),20,mm Hg,Table 2

Sorensen_1988_ActaNeurolScand,Sorensen_1988_ActaNeurolScand,P21,Baseline,23,Female,Cout
(Before),0.059,ml.mm Hg-1.min-1,Table 2

Sorensen_1988_ActaNeurolScand,Sorensen_1988_ActaNeurolScand,P21,ACZ_plus_Diuretic_Chronic,23,Female,Cout
(After),0.052,ml.mm Hg-1.min-1,Table 2

Sorensen_1988_ActaNeurolScand,Sorensen_1988_ActaNeurolScand,P22,Baseline,58,Male,ICP
(Before),25,mm Hg,Table 2

Sorensen_1988_ActaNeurolScand,Sorensen_1988_ActaNeurolScand,P22,ACZ_plus_Diuretic_Chronic,58,Male,ICP
(After),25,mm Hg,Table 2

Sorensen_1988_ActaNeurolScand,Sorensen_1988_ActaNeurolScand,P22,Baseline,58,Male,Cout
(Before),0.021,ml.mm Hg-1.min-1,Table 2

Sorensen_1988_ActaNeurolScand,Sorensen_1988_ActaNeurolScand,P22,ACZ_plus_Diuretic_Chronic,58,Male,Cout
(After),0.043,ml.mm Hg-1.min-1,Table 2

Sorensen_1988_ActaNeurolScand,Sorensen_1988_ActaNeurolScand,P24,Baseline,66,Female,ICP
(Before),35,mm Hg,Table 2

Sorensen_1988_ActaNeurolScand,Sorensen_1988_ActaNeurolScand,P24,ACZ_plus_Diuretic_Chronic,66,Female,ICP
(After),18,mm Hg,Table 2

Sorensen_1988_ActaNeurolScand,Sorensen_1988_ActaNeurolScand,P24,Baseline,66,Female,Cout
(Before),0.022,ml.mm Hg-1.min-1,Table 2

Sorensen_1988_ActaNeurolScand,Sorensen_1988_ActaNeurolScand,P24,ACZ_plus_Diuretic_Chronic,66,Female,Cout
(After),0.033,ml.mm Hg-1.min-1,Table 2
